JPY 330.0
(-0.3%)
Year | Revenue | Revenue Growth |
---|---|---|
2024 | - JPY | -100.0% |
2023 | 2.35 Billion JPY | 10128.06% |
2022 | 22.97 Million JPY | -98.36% |
2021 | 1.4 Billion JPY | -33.33% |
2020 | 2.1 Billion JPY | 2000.0% |
2019 | 100 Million JPY | -50.0% |
2018 | 200 Million JPY | -33.33% |
2017 | 300 Million JPY | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q3 | - JPY | 0.0% |
2024 Q4 | - JPY | 0.0% |
2024 Q2 | - JPY | 0.0% |
2024 Q1 | - JPY | 0.0% |
2023 Q2 | - JPY | 0.0% |
2023 FY | 2.35 Billion JPY | 10128.06% |
2023 Q1 | - JPY | 0.0% |
2023 Q4 | - JPY | -100.0% |
2023 Q3 | 2.35 Billion JPY | 0.0% |
2022 Q2 | - JPY | -100.0% |
2022 FY | 22.97 Million JPY | -98.36% |
2022 Q4 | - JPY | 0.0% |
2022 Q3 | - JPY | 0.0% |
2022 Q1 | 22.97 Million JPY | -98.07% |
2021 FY | 1.4 Billion JPY | -33.33% |
2021 Q4 | 1.19 Billion JPY | 0.0% |
2021 Q3 | 1.19 Billion JPY | 0.0% |
2021 Q2 | - JPY | -100.0% |
2021 Q1 | 210 Million JPY | -87.65% |
2020 FY | 2.1 Billion JPY | 2000.0% |
2020 Q4 | 1.7 Billion JPY | 325.0% |
2020 Q3 | 400 Million JPY | 0.0% |
2020 Q2 | 400 Million JPY | 0.0% |
2020 Q1 | - JPY | 0.0% |
2019 FY | 100 Million JPY | -50.0% |
2019 Q4 | - JPY | 0.0% |
2018 FY | 200 Million JPY | -33.33% |
2017 FY | 300 Million JPY | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
KOHJIN BIO CO LTD | 4.77 Billion JPY | 100.0% |
PRISM BioLab Co.,LTD | 112.92 Million JPY | 100.0% |
GNI Group Ltd. | 26.01 Billion JPY | 100.0% |
Linical Co., Ltd. | 12.3 Billion JPY | 100.0% |
Trans Genic Inc. | 13.08 Billion JPY | 100.0% |
MEDINET Co., Ltd. | 661.54 Million JPY | 100.0% |
Soiken Holdings Inc. | 5.15 Billion JPY | 100.0% |
Cytori Cell Research Institute, Inc. | 1.56 Billion JPY | 100.0% |
AnGes, Inc. | 152.98 Million JPY | 100.0% |
OncoTherapy Science, Inc. | 610.11 Million JPY | 100.0% |
Nxera Pharma Co., Ltd. | 12.76 Billion JPY | 100.0% |
Immuno-Biological Laboratories Co., Ltd. | 816.7 Million JPY | 100.0% |
NanoCarrier Co., Ltd. | 135.5 Million JPY | 100.0% |
Carna Biosciences, Inc. | 1.62 Billion JPY | 100.0% |
CanBas Co., Ltd. | - JPY | NaN% |
D. Western Therapeutics Institute, Inc. | 428.36 Million JPY | 100.0% |
RaQualia Pharma Inc. | 1.9 Billion JPY | 100.0% |
Chiome Bioscience Inc. | 682.46 Million JPY | 100.0% |
Kidswell Bio Corporation | 2.43 Billion JPY | 100.0% |
PeptiDream Inc. | 28.71 Billion JPY | 100.0% |
Oncolys BioPharma Inc. | 63.03 Million JPY | 100.0% |
Ribomic Inc. | - JPY | NaN% |
SanBio Company Limited | - JPY | NaN% |
Healios K.K. | 121 Million JPY | 100.0% |
BrightPath Biotherapeutics Co., Ltd. | 72 Thousand JPY | 100.0% |
Kubota Pharmaceutical Holdings Co., Ltd. | 39.88 Million JPY | 100.0% |
Delta-Fly Pharma, Inc. | - JPY | NaN% |
CellSource Co., Ltd. | 4.51 Billion JPY | 100.0% |
FunPep Company Limited | 530 Thousand JPY | 100.0% |
Kringle Pharma, Inc. | 69.25 Million JPY | 100.0% |
Stella Pharma Corporation | 269.49 Million JPY | 100.0% |
TMS Co., Ltd. | - JPY | NaN% |
Noile-Immune Biotech Inc. | 316.81 Million JPY | 100.0% |
Cuorips Inc. | 23.1 Million JPY | 100.0% |
K Pharma,Inc. | 1 Billion JPY | 100.0% |
Takara Bio Inc. | 43.5 Billion JPY | 100.0% |
ReproCELL Incorporated | 2.42 Billion JPY | 100.0% |
PhoenixBio Co., Ltd. | 1.71 Billion JPY | 100.0% |
StemCell Institute Inc. | 2.48 Billion JPY | 100.0% |
Japan Tissue Engineering Co., Ltd. | 2.51 Billion JPY | 100.0% |
CellSeed Inc. | 190.13 Million JPY | 100.0% |